HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Fixed-Dose Pertuzumab/Trastuzumab Combo Nears EU Approval for HER2+ Breast Cancer

November 15th 2020

November 15, 2020 - The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for the fixed-dose combination of pertuzumab plus trastuzumab with hyaluronidase-zzxf for administration via subcutaneous injection in combination with intravenous chemotherapy in the treatment of patients with early and metastatic HER2-positive breast cancer

Dr. Bagegni on the Safety Profile of T-DM1 in Early-Stage HER2+ Breast Cancer

November 12th 2020

Nusayba Bagegni, MD, discusses the safety profile of ado-trastuzumab emtansine in early-stage HER2-positive breast cancer.

Dr. Jhaveri on Outlining First-Line Treatment in HER2+ Breast Cancer

November 5th 2020

Komal Jhaveri, MD, FACP, discusses the importance of outlining the first-line treatment course for patients with HER2-positive breast cancer.

Tucatinib Triplet Takes Up Residence in Third-Line Metastatic HER2+ Breast Cancer

November 2nd 2020

Elisavet Paplomata, MD, discusses the lack of standard third-line regimens for patients with metastatic HER2-positive breast cancer, especially for those with brain metastases.

Tan Speaks to Benefits of Fixed-Dose Pertuzumab/Trastuzumab Combo in HER2+ Breast Cancer

October 30th 2020

Antoinette R. Tan, MD, discusses the FDA approval of the fixed-dose combination of SC pertuzumab and trastuzumab with hyaluronidase, in combination with IV chemotherapy in HER2-positive breast cancer.

Dr. Tripathy on Treatment De-Escalation in HER2+ Breast Cancer

October 28th 2020

Debu Tripathy, MD, discusses treatment de-escalation in HER2-positive breast cancer.

Dr. Gradishar on the Expanding Role of Trastuzumab Deruxtecan in HER2+ Breast Cancer

October 28th 2020

William J. Gradishar, MD, discusses the expanding role of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.

Dr. Isaacs on the Evolving Treatment Landscape in HER2+ Breast Cancer

October 27th 2020

Claudine Isaacs, MD, discusses the rapidly evolving HER2-positive breast cancer armamentarium.

Dr. Tolaney on Escalating Versus De-Escalating Therapies in HER2+ Breast Cancer

October 23rd 2020

Sara M. Tolaney, MD, MPH, discusses escalating versus de-escalating therapies in HER2-positive breast cancer.

Dr. Tolaney on Data With Trastuzumab Deruxtecan in HER2+ Breast Cancer Brain Metastases

October 22nd 2020

Sara M. Tolaney, MD, MPH, discusses the potential role of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive breast cancer and brain metastases.

O’Regan Weighs Escalation, De-Escalation Approaches in Early-Stage HER2+ Breast Cancer

October 21st 2020

In an interview with OncLive Ruth O’Regan, MD, discusses the challenges faced with personalizing treatment in early-stage HER2-positive breast cancer

Practicing Oncologists Debate New Tactics for Brain Metastases in HER2+ Breast Cancer

October 21st 2020

New approaches for treating patients with HER2-positive metastatic breast cancer are showing signs of efficacy against brain metastases, generating excitement about the potential to make critical advances and sparking questions about optimal sequencing.

Dr. Paplomata on the Role of Tucatinib/Trastuzumab/Capecitabine in HER2+ Metastatic Breast Cancer

October 19th 2020

Elisavet Paplomata, MD, discusses the role of tucatinib in combination with trastuzumab and capecitabine in HER2-positive metastatic breast cancer.

Dr. O’Regan on the Role of Therapy Escalation in HER2+ Breast Cancer

October 16th 2020

Ruth O’Regan, MD, discusses the role of therapy escalation in HER2-positive breast cancer.

Tolaney Touches on HER2+ -Low Breast Cancer Testing, Possibilities, and Challenges

October 16th 2020

Sara M. Tolaney, MD, MPH, discusses the challenges in treating patients with heterogenous HER2 expression and what treatments could potentially improve outcomes for this subgroup.

Dr. Paplomata on Managing Trastuzumab Deruxtecan–Induced ILD in HER2+ Breast Cancer

October 13th 2020

Elisavet Paplomata, MD, discusses management strategies for fam-trastuzumab deruxtecan-nxki–induced interstitial lung disease in HER2-positive breast cancer.

Dr. O’Regan on the Risk of Cardiomyopathy With Trastuzumab in HER2+ Breast Cancer

October 12th 2020

Ruth O’Regan, MD, discusses the risk of cardiomyopathy associated with trastuzumab in HER2-positive breast cancer.

Dr. Gradishar on the Treatment Landscape in Metastatic HER2+ Breast Cancer

October 9th 2020

William J. Gradishar, MD, discusses the current treatment landscape in metastatic HER2-positive breast cancer.

Dr. Lin on Treatment Challenges in HER2+ Breast Cancer and Brain Metastases

October 8th 2020

Nancy U. Lin, MD, discusses the challenges faced in the treatment of patients with HER2-positive breast cancer and brain metastases.

pCR Put Forth as a Surrogate Marker for Improved Survival in Early HER2+ Breast Cancer

October 8th 2020

Women with early-stage HER2-positive breast cancer who achieved a pathologic complete response to neoadjuvant HER2-directed therapy experienced prolonged event-free survival and overall survival versus those who did not.